Author Archive: Celia Economides

Celia was a Manager of Investor Relations & Business Development at BIO.

Latest Posts

LifeCycle Pharma announces Phase 2 results for liver transplant patients study

LifeCycle Pharma A/S (CSE:LCP) announced positive results from a 12 month extension phase of the Phase 2 clinical study of LCP-Tacro tablets in stable liver transplant patients. LCP-Tacro is a once daily immunosuppression drug to prevent rejection after organ transplantation. These new data demonstrated that LCP-Tacro tablets for stable liver patients continues in the extension phase of the study to have a potential best-in-class profile when compared to the currently marketed twice daily tacrolimus capsule, Read More >

Business of Biotech  |  Leave a comment  |  Email This Post
Tags: ,